PARP1 and ovarian cancer: The possibility of personalising the treatment according to the mutational state, as occurs in the choice of treatments with platinum compounds and poly (ADP-ribose) polymerase 1 (PARP1) inhibitors in patients with ovarian cancer, has extended the recommendation to most international guidelines [19–20].